Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelmastobart plus capecitabine in metastatic colorectal cancer resistant or intolerant to oxaliplatin and irinotecan
KCT0009138Phase 2Not yet recruiting
- Sponsor
- STCube
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of nelmastobart in metastatic colorectal adenocarcinoma (mCRC), sponsored by STCube. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
nelmastobart
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on KCT0009138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009138.